GlassScriptPhysician profile
Andrew M Kazdan
NPI 1811963903
$4,827.71
in general payments reported to CMS, 2019-2025
35 companies · $1,362 in 2025
The $1,362 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,114 · 2020: $243 · 2022: $291 · 2023: $887 · 2024: $931 · 2025: $1,362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,180.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $880.60 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $584.46 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $454.36 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $367.24 | 2019-2025 | |
| Amgen INC. | $357.81 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $319.69 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $251.21 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $198.40 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $194.79 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.50 | 2019-2025 | Jardiance, Tradjenta |
| Abbott Laboratories | $120.12 | 2019-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $115.64 | 2019-2024 | Trintellix |
| Ironwood Pharmaceuticals, INC | $110.39 | 2022-2024 | Linzess |
| E.R. Squibb & Sons, L.L.C. | $89.40 | 2019-2025 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.72 | 2019-2025 | Xifaxan |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $68.63 | 2023-2025 | |
| Astellas Pharma US INC | $48.42 | 2019 | |
| Allergan, INC. | $42.63 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.16 | 2025 | Caplyta |
| Tris Pharma INC | $36.77 | 2024 | Dyanavel Xr |
| Regeneron Healthcare Solutions, INC. | $35.65 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $33.21 | 2019 | |
| Axsome Therapeutics, INC. | $29.95 | 2025 | Symbravo |
| Amarin Pharma, INC. | $26.87 | 2019 | |
| Esperion Therapeutics, INC. | $23.94 | 2025 | Nexletol |
| Biohaven Pharmaceutical Holding Company LTD. | $23.20 | 2022 | |
| Mannkind Corporation | $21.44 | 2023 | Afrezza |
| Sumitomo Pharma America, INC. | $20.19 | 2023 | Gemtesa |
| Averitas Pharma INC. | $20.11 | 2024 | Qutenza |
| Endo Pharmaceuticals INC. | $18.96 | 2019 | |
| Valinor Pharma, LLC | $18.31 | 2025 | Movantik |
| Jazz Pharmaceuticals INC. | $16.76 | 2019 | |
| Shire North American Group INC | $16.11 | 2019 | |
| Exact Sciences Corporation | $13.99 | 2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Kazdan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.